{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:11:47Z","timestamp":1790331107712,"version":"4.1.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>\u0130ntroduction<\/jats:title>\n                    <jats:p>The standard treatment for hormone receptor-positive and HER2-negative metastatic breast cancer is a combination of CDK4\/6 inhibitors and endocrine therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>In this case, our aim was to demonstrate the safety and effectiveness of ribociclib in a patient with metastatic breast cancer undergoing hemodialysis three days a week.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; Outcome<\/jats:title>\n                    <jats:p>A 59-year-old female patient with end-stage kidney disease who undergoes hemodialysis was diagnosed with metastatic breast cancer. The tumour is hormone receptor positive and HER2 negative. She received ribociclib with a reduced dose due to haematological toxicity, as well as letrozole and denosumab due to bone metastasis. PET\/CT scans revealed that the primary tumour had regressed by 50%, with partial regression of the metabolic activity of the bone metastases. Ribociclib was administered safely and effectively for nine months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We presented our experience of using ribociclib in a patient with metastatic breast cancer who was receiving hemodialysis. Ribociclib was administered safely, and a response to the treatment was achieved.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261423942","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T18:12:11Z","timestamp":1771524731000},"page":"1398-1400","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safe use of ribociclib in a patient with HR+\/HER2\u2212 metastatic breast cancer receiving chronic hemodialysis"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-6815","authenticated-orcid":false,"given":"Dilek","family":"\u00c7a\u011flayan","sequence":"first","affiliation":[{"name":"Nev\u015fehir State Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6043-4703","authenticated-orcid":false,"given":"Melek","family":"\u00c7a\u011flayan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Giresun Training and Research Hospital, Giresun, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00228-0"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy155"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-05125-4"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30165-3"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101604"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2024.01.003"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1185"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2369"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1133"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00615"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000091"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0131-1"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1950"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.599"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01206-2"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00365.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.09.007"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.09.033"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000484962"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194941"},{"key":"e_1_3_2_23_2","first-page":"851","article-title":"High creatinine level secondary to use of CDK 4\/6 inhibitor treatment (palbociclib and ribociclib) + endocrine therapy (ET)","volume":"34","author":"Keskinkilic M","unstructured":"Keskinkilic M, Semiz HS, Yavuzsen T, et al. High creatinine level secondary to use of CDK 4\/6 inhibitor treatment (palbociclib and ribociclib) + endocrine therapy (ET). J Coll Physicians Surg Pak 2024, Jul; 34: 851\u2013853.","journal-title":"J Coll Physicians Surg Pak"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.11.033"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261423942","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261423942","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261423942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:56:26Z","timestamp":1790330186000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261423942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10781552261423942"],"URL":"https:\/\/doi.org\/10.1177\/10781552261423942","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]}}}